This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
12 Nov 2012

WIN Consortium announces collaboration with Pfizer

The WIN Consortium has confirmed Pfizer as its first pharmaceutical partner.

Pfizer has become the first pharmaceutical partner of the Worldwide Innovative Network (WIN) Consortium - a global network of academic, industry and patient advocacy organisations working to advance personalised cancer care.

The pharmaceutical giant will play an important role in shaping the consortium's achievements by helping to speed up access to personalised medicine.

According to the WIN Consortium, Pfizer's goals and capabilities - such as its commitment to the development of targeted drugs and its breadth of experience in the field of oncology - are aligned with the group's own mission.

Professor Alexander Eggermont, vice-chairman of the WIN Consortium, said that the advancement of personalised cancer medicine "requires collaboration and partnerships between multiple sectors of the health sciences community".

"We are proud to have Pfizer as WIN's first pharmaceutical partner and believe that this collaboration will benefit cancer patients worldwide," he revealed.

Dr Richard Buller, vice-president of translational oncology for Pfizer's oncology business unit, added that the company is "excited" to join the consortium, which he described as a "unique forum to collectively share insights, exchange ideas and positively impact cancer patients".
 

Related News